Document is current
Any future updates will be listed below
-
Authors
Witzel, Simon https://orcid.org/0000-0003-1841-954X
Frauhammer, Felix
Steinacker, Petra
Devos, David
Pradat, Pierre-François
Meininger, Vincent
Halbgebauer, Steffen
Oeckl, Patrick
Schuster, Joachim
Anders, Simon
Dorst, Johannes
Otto, Markus
Ludolph, Albert C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00868166 at ClinicalTrials.govnct02306590 at ClinicalTrials.govDocuments that mention this clinical trial
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
https://doi.org/10.1186/s40035-021-00257-y
Documents that mention this clinical trial
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
https://doi.org/10.1186/s40035-021-00257-y
-
Funding
Funding for this research was provided by:
Universität Ulm
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 7 August 2021
First Online: 26 August 2021
Declarations
:
: The observational study used for model development (MND-net, site Ulm) was approved by the independent Ethics Committee of Ulm University (Number 19/12). Written informed consent was obtained from all participants. LIPCAL ALS (ClinicalTrials.gov: NCT02306590) and MitoTarget ALS (ClinicalTrials.gov: NCT:00868166) were approved by the independent ethics committees at each study site. Written informed consent was obtained from all participants. Trial Registration: NCT00868166, registered March 23, 2009; NCT02306590, registered December 2, 2014.
: Not applicable.
: The authors declare that they have no competing interests.
